ArticleBMC cancer2024

Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach.

Ash Bullement et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.